Skip to main content
Erschienen in: General Thoracic and Cardiovascular Surgery 6/2014

01.06.2014 | Original Article

Pneumonectomy for node-positive non-small cell lung cancer: can it be a treatment option for N2 disease?

verfasst von: Satona Tanaka, Minoru Aoki, Hiroyuki Ishikawa, Yosuke Otake

Erschienen in: General Thoracic and Cardiovascular Surgery | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Objective

The feasibility of multimodality therapy in patients with node-positive non-small cell lung cancer (NSCLC) requiring pneumonectomy and the role of pneumonectomy in N2 disease remain controversial. This study evaluated outcomes in patients with node-positive NSCLC undergoing pneumonectomy in a community hospital.

Methods

Perioperative and long-term outcomes of 37 patients with node-positive (pN1–2) NSCLC undergoing pneumonectomy from September 1994 to April 2010 as a clinical practice were retrospectively analyzed.

Results

Twenty patients received induction therapy, and 17 received preoperative chemoradiation (30–40 Gy). Fifteen patients and 22 patients underwent right and left pneumonectomy, respectively. A postoperative complication occurred in 8 patients. In-hospital mortality occurred in 1 patient. Induction therapy did not increase the operative risk including operative time, blood loss and postoperative complications. Nineteen patients were given a diagnosis of pN2. Although 7 bulky N2 patients and 10 multi-station N2 patients were included, 5-year overall survival was 34.3 % in pN1 and 28.0 % in pN2 (p = 0.998), respectively. Twenty-three patients received additional postoperative therapy. Five patients died within 3 months postoperatively due to distant metastases. Induction therapy and laterality did not influence survival. Extended resection, such as vagus nerve or chest wall resection, predicted an unfavorable outcome in multivariate analysis (Hazard ratio 2.81, p = 0.032).

Conclusions

The safety and acceptable long-term outcome of pneumonectomy as a general clinical practice were shown for both pN1 and pN2 patients with various preoperative or postoperative therapies. Extended resection due to the extrapleural or extranodal involvement of tumor was an unfavorable prognostic factor.
Literatur
1.
Zurück zum Zitat Licker M, Spiliopoulos A, Frey JG, Robert J, Höhn L, de Perrot M, et al. Risk factors for early mortality and major complications following pneumonectomy for non-small cell carcinoma of the lung. Chest. 2002;121:1890–7.PubMedCrossRef Licker M, Spiliopoulos A, Frey JG, Robert J, Höhn L, de Perrot M, et al. Risk factors for early mortality and major complications following pneumonectomy for non-small cell carcinoma of the lung. Chest. 2002;121:1890–7.PubMedCrossRef
2.
Zurück zum Zitat Ichiki Y, Nagashima A, Chikaishi Y, Yasuda M. Pneumonectomy for non-small cell lung cancer. Surg Today. 2012;42:830–4.PubMedCrossRef Ichiki Y, Nagashima A, Chikaishi Y, Yasuda M. Pneumonectomy for non-small cell lung cancer. Surg Today. 2012;42:830–4.PubMedCrossRef
3.
Zurück zum Zitat Krasna MJ. COUNTERPOINT: Pneumonectomy after chemoradiation: the risks of trimodality therapy. J Thorac Cardiovasc Surg. 2009;138:295–9.PubMedCrossRef Krasna MJ. COUNTERPOINT: Pneumonectomy after chemoradiation: the risks of trimodality therapy. J Thorac Cardiovasc Surg. 2009;138:295–9.PubMedCrossRef
4.
Zurück zum Zitat Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86.PubMedCrossRef Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86.PubMedCrossRef
5.
Zurück zum Zitat Veeramachaneni NK, Feins RH, Stephenson BJ, Edwards LJ, Fernandez FG. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg. 2012;94:922–6.PubMedCrossRef Veeramachaneni NK, Feins RH, Stephenson BJ, Edwards LJ, Fernandez FG. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg. 2012;94:922–6.PubMedCrossRef
6.
Zurück zum Zitat Amano J, Kuwano H, Yokomise H. Thoracic and cardiovascular surgery in Japan during 2011 (Annual report by The Japanese Association for Thoracic Surgery). Gen Thorac Cardiovasc Surg. 2013;61:578–607.PubMedCrossRef Amano J, Kuwano H, Yokomise H. Thoracic and cardiovascular surgery in Japan during 2011 (Annual report by The Japanese Association for Thoracic Surgery). Gen Thorac Cardiovasc Surg. 2013;61:578–607.PubMedCrossRef
7.
Zurück zum Zitat Kunitoh H, Suzuki K. How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer. Br J Cancer. 2007;96:1498–503.PubMedCentralPubMedCrossRef Kunitoh H, Suzuki K. How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer. Br J Cancer. 2007;96:1498–503.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Seder CW, Allen MS, Cassivi SD, Deschamps CD, Nichols FC, Olivier KR, et al. Stage IIIA non-small cell lung cancer: morbidity and mortality of three distinct multimodality regimens. Ann Thorac Surg. 2013;95:1708–16.PubMedCrossRef Seder CW, Allen MS, Cassivi SD, Deschamps CD, Nichols FC, Olivier KR, et al. Stage IIIA non-small cell lung cancer: morbidity and mortality of three distinct multimodality regimens. Ann Thorac Surg. 2013;95:1708–16.PubMedCrossRef
9.
Zurück zum Zitat Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations. Chest. 2000;118:123–8.PubMedCrossRef Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations. Chest. 2000;118:123–8.PubMedCrossRef
10.
Zurück zum Zitat Yokomise H, Gotoh M, Okamoto T, Yamamoto Y, Ishikawa S, Nakashima T, et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:1179–85.PubMedCrossRef Yokomise H, Gotoh M, Okamoto T, Yamamoto Y, Ishikawa S, Nakashima T, et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:1179–85.PubMedCrossRef
11.
Zurück zum Zitat Koshy M, Fedewa SA, Malik R, Ferguson MK, Vigneswaran WT, Feldman L, et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol. 2013;8:915–22.PubMedCrossRef Koshy M, Fedewa SA, Malik R, Ferguson MK, Vigneswaran WT, Feldman L, et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol. 2013;8:915–22.PubMedCrossRef
12.
Zurück zum Zitat Shah AA, Berry MF, Tzao C, Gandhi M, Worni M, Pietrobon R, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg. 2012;93:1807–12.PubMedCrossRef Shah AA, Berry MF, Tzao C, Gandhi M, Worni M, Pietrobon R, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg. 2012;93:1807–12.PubMedCrossRef
13.
Zurück zum Zitat Kim AW, Liptay MJ, Bonomi P, Warren WH, Basu S, Farlow EC, et al. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011;92:233–41.PubMedCrossRef Kim AW, Liptay MJ, Bonomi P, Warren WH, Basu S, Farlow EC, et al. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011;92:233–41.PubMedCrossRef
14.
Zurück zum Zitat Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg. 2003;125:254–60.PubMedCrossRef Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg. 2003;125:254–60.PubMedCrossRef
15.
Zurück zum Zitat Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna R Jr, et al. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg. 1993;105:97–104.PubMed Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna R Jr, et al. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg. 1993;105:97–104.PubMed
16.
Zurück zum Zitat Kim AW, Boffa DJ, Wang Z, Detterbeck FC. An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012;143:55–63.PubMedCrossRef Kim AW, Boffa DJ, Wang Z, Detterbeck FC. An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012;143:55–63.PubMedCrossRef
17.
Zurück zum Zitat d’Amato TA, Ashrafi AS, Schuchert MJ, Alshehab DS, Seely AJ, Shamji FM, et al. Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer. Ann Thorac Surg. 2009;88:1079–85.PubMedCrossRef d’Amato TA, Ashrafi AS, Schuchert MJ, Alshehab DS, Seely AJ, Shamji FM, et al. Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer. Ann Thorac Surg. 2009;88:1079–85.PubMedCrossRef
18.
Zurück zum Zitat Shapiro M, Swanson SJ, Wright CD, Chin C, Sheng S, Wisnivesky J, et al. Predictors of major morbidity and mortality after pneumonectomy utilizing the Society for thoracic surgeons general thoracic surgery database. Ann Thorac Surg. 2010;90:927–34.PubMedCrossRef Shapiro M, Swanson SJ, Wright CD, Chin C, Sheng S, Wisnivesky J, et al. Predictors of major morbidity and mortality after pneumonectomy utilizing the Society for thoracic surgeons general thoracic surgery database. Ann Thorac Surg. 2010;90:927–34.PubMedCrossRef
19.
Zurück zum Zitat Shah AA, Worni M, Kelsey CR, Onaitis MW, D’Amico TA, Berry MF. Does pneumonectomy have a role in the treatment of stage IIIA non-small cell lung cancer? Ann Thorac Surg. 2013;95:1700–7.PubMedCrossRef Shah AA, Worni M, Kelsey CR, Onaitis MW, D’Amico TA, Berry MF. Does pneumonectomy have a role in the treatment of stage IIIA non-small cell lung cancer? Ann Thorac Surg. 2013;95:1700–7.PubMedCrossRef
20.
Zurück zum Zitat Thibout Y, Guibert B, Bossard N, Tronc F, Tiffet O, de la Roche E, et al. Is pneumonectomy after induction chemotherapy for non-small cell lung cancer a reasonable procedure? A multicenter retrospective study of 228 cases. J Thorac Oncol. 2009;4:1496–503.PubMedCrossRef Thibout Y, Guibert B, Bossard N, Tronc F, Tiffet O, de la Roche E, et al. Is pneumonectomy after induction chemotherapy for non-small cell lung cancer a reasonable procedure? A multicenter retrospective study of 228 cases. J Thorac Oncol. 2009;4:1496–503.PubMedCrossRef
21.
Zurück zum Zitat Mansour Z, Kochetkova EA, Ducrocq X, Vasilescu MD, Maxant G, Buggenhout A, et al. Induction chemotherapy does not increase the operative risk of pneumonectomy! Eur J Cardiothorac Surg. 2007;31:181–5.PubMedCrossRef Mansour Z, Kochetkova EA, Ducrocq X, Vasilescu MD, Maxant G, Buggenhout A, et al. Induction chemotherapy does not increase the operative risk of pneumonectomy! Eur J Cardiothorac Surg. 2007;31:181–5.PubMedCrossRef
22.
Zurück zum Zitat Fernandez FG, Force SD, Pickens A, Kilgo PD, Luu T, Miller DL. Impact of laterality on early and late survival after pneumonectomy. Ann Thorac Surg. 2011;92:244–9.PubMedCrossRef Fernandez FG, Force SD, Pickens A, Kilgo PD, Luu T, Miller DL. Impact of laterality on early and late survival after pneumonectomy. Ann Thorac Surg. 2011;92:244–9.PubMedCrossRef
23.
Zurück zum Zitat Kim AW, Faber LP, Warren WH, Basu S, Wightman SC, Weber JA, et al. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does “side” really matter? Ann Thorac Surg. 2009;88:937–43.PubMedCrossRef Kim AW, Faber LP, Warren WH, Basu S, Wightman SC, Weber JA, et al. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does “side” really matter? Ann Thorac Surg. 2009;88:937–43.PubMedCrossRef
24.
Zurück zum Zitat van Meerbeeck JP, Damhuis RA, Vos de Wael ML. High postoperative risk after pneumonectomy in elderly patients with right-sided lung cancer. Eur Respir J. 2002;19:141–5.PubMedCrossRef van Meerbeeck JP, Damhuis RA, Vos de Wael ML. High postoperative risk after pneumonectomy in elderly patients with right-sided lung cancer. Eur Respir J. 2002;19:141–5.PubMedCrossRef
25.
Zurück zum Zitat Weder W, Collaud S, Eberhardt WE, Hillinger S, Welter S, Stahel R, et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg. 2010;139:1424–30.PubMedCrossRef Weder W, Collaud S, Eberhardt WE, Hillinger S, Welter S, Stahel R, et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg. 2010;139:1424–30.PubMedCrossRef
26.
Zurück zum Zitat Decaluwe H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg. 2009;36:433–9.PubMedCrossRef Decaluwe H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg. 2009;36:433–9.PubMedCrossRef
27.
Zurück zum Zitat Paul S, Mirza F, Port JL, Lee PC, Stiles BM, Kansler AL, et al. Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. J Thorac Cardiovasc Surg. 2011;141:48–58.PubMedCrossRef Paul S, Mirza F, Port JL, Lee PC, Stiles BM, Kansler AL, et al. Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. J Thorac Cardiovasc Surg. 2011;141:48–58.PubMedCrossRef
28.
Zurück zum Zitat Cerfolio RJ, Bryant AS, Jones VL, Cerfolio RM. Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg. 2009;35:718–23.PubMedCrossRef Cerfolio RJ, Bryant AS, Jones VL, Cerfolio RM. Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg. 2009;35:718–23.PubMedCrossRef
29.
Zurück zum Zitat Krasna MJ, Gamliel Z, Burrows WM, Sonett JR, Kwong KF, Edelman MJ, et al. Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation. Ann Thorac Surg. 2010;89:200–6.PubMedCrossRef Krasna MJ, Gamliel Z, Burrows WM, Sonett JR, Kwong KF, Edelman MJ, et al. Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation. Ann Thorac Surg. 2010;89:200–6.PubMedCrossRef
30.
Zurück zum Zitat Borri A, Leo F, Veronesi G, Solli P, Galetta D, Gasparri R, et al. Extended pneumonectomy for non-small cell lung cancer: morbidity, mortality, and long-term results. J Thorac Cardiovasc Surg. 2007;134:1266–72.PubMedCrossRef Borri A, Leo F, Veronesi G, Solli P, Galetta D, Gasparri R, et al. Extended pneumonectomy for non-small cell lung cancer: morbidity, mortality, and long-term results. J Thorac Cardiovasc Surg. 2007;134:1266–72.PubMedCrossRef
Metadaten
Titel
Pneumonectomy for node-positive non-small cell lung cancer: can it be a treatment option for N2 disease?
verfasst von
Satona Tanaka
Minoru Aoki
Hiroyuki Ishikawa
Yosuke Otake
Publikationsdatum
01.06.2014
Verlag
Springer Japan
Erschienen in
General Thoracic and Cardiovascular Surgery / Ausgabe 6/2014
Print ISSN: 1863-6705
Elektronische ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-014-0380-3

Weitere Artikel der Ausgabe 6/2014

General Thoracic and Cardiovascular Surgery 6/2014 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Traumatologische Notfälle Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.